Drug Profile
Research programme: MicAbody antibodies - Xyphos
Alternative Names: MicAbody™ proteins - XyphosLatest Information Update: 28 Oct 2021
Price :
$50
*
At a glance
- Originator AvidBiotics Corp.
- Developer Xyphos
- Class Antibodies; Antineoplastics; Antivirals; Recombinant fusion proteins
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Cytomegalovirus infections
Most Recent Events
- 28 Oct 2021 No recent reports of development identified for preclinical development in Cancer in USA
- 28 Oct 2021 No recent reports of development identified for research development in Cytomegalovirus infections in USA
- 03 Feb 2021 AbSci enters into manufacturing and discovery agreement with Xyphos Biosciences for MicAbody™ development